Orthofix Medical Inc. reported its financial results for the second quarter of 2025, showing net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs. Excluding the M6® discs, pro forma net sales reached $200.7 million, marking an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to the second quarter of 2024. The U.S. Spine Fixation segment experienced net sales growth of 5% and procedure volume growth of 7% compared to the same period last year. The company reported a net loss of $14.1 million, or $0.36 per share, on a reported basis. However, non-GAAP pro forma adjusted EBITDA was $20.6 million for the second quarter of 2025, representing a $4.0 million increase compared to the $16.6 million reported for the second quarter of 2024, reflecting a 24.1% growth over the prior year. Orthofix reaffirmed its full-year 2025 financial guidance and highlighted strategic initiatives, such as accelerating distributor transitions in underpenetrated U.S. territories, which are contributing to the company's ongoing transformation efforts.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。